Amelioration of experimental autoimmune myocarditis through activation of invariant natural killer T cells by administration of α-galactosylceramide

Kazuhisa Yoshino,1 Masashi Satoh,2,3 Toshitsugu Iwayama,2 Shusaku Kobayashi,2 Hirotsugu Okamoto,4 Koji Eshima,2,3 Hiroshi Watarai,5,6 Kazuya Iwabuchi2,3

1 Program in Anesthesiology, Kitasato University Graduate School of Medical Sciences
2 Program in Cellular Immunology, Kitasato University Graduate School of Medical Sciences
3 Department of Immunology, Kitasato University School of Medicine
4 Department of Anesthesiology, Kitasato University School of Medicine
5 Division of Stem Cell Cellomics, Institute of Medical Sciences, The University of Tokyo
6 Department of Immunology and Stem Cell Biology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University

Background: NKT cells recognize glycolipid antigens such as α-GC in the context of the CD1d molecule and play an ameliorating role by producing immunoregulatory cytokines in models of ischemic heart disease, e.g., acute myocardial infarction and ischemia/reperfusion injury.

Objective: To examine whether iNKT cells also play an ameliorating role for EAMC, α-GC was administered to activate iNKT cells at the time of immunization for induction of EAMC.

Methods: EAMC was induced in BALB/c mice or iNKT-deficient TRAJ18-/- mice by immunizing subcutaneously with a peptide (residue 614-629) of mouse cardiac myosin heavy chain-α emulsified with Complete Freund's Adjuvant followed by additional immunization on day 7. Vehicle or α-GC was administered as a mixture of the first immunizing emulsion. Three weeks later, histological and gene-expression analyses were performed to examine the effects.

Results: The mice inoculated with α-GC for immunization showed reduced TNF-α and increased IL-10 (interleukin-10) expression, with fewer infiltrated inflammatory cells. Accordingly, the fibrotic lesion area was reduced in the heart. EAMC induced in iNKT-cell deficient mice was aggravated in comparison with that induced in BALB/c mice with an enhanced fibrotic lesion area on day 21 after immunization.

Conclusion: The presence of iNKT cells and activation of iNKT cells on immunization ameliorated the inflammation of EAMC.

Key words: cardiac remodeling, cardiac macrophages, NKT cell ligands, immunoregulation, antigen-presenting cells, α-GC

Abbreviations: NKT, natural killer T; α-GC, α-galactosylceramide; iNKT, invariant NKT; EAMC, experimental autoimmune myocarditis; TNF-α, tumor necrosis factor-α; TCR, T-cell antigen receptor; Ag, antigen; AMI, acute myocardial infarction; Treg, regulatory T; MyHC-α, cardiac myosin heavy chain α-isof orm; PTX, Bordetella pertussis toxin; CFA, Complete Freund's Adjuvant; PBS, phosphate buffered saline; H&E, hematoxylin and eosin; dLN, draining lymph node; APC, antigen-presenting cell; PCR, polymerase chain reaction; MΦ, macrophages; Mo, monocytes; CMNC, cardiac mononuclear cell; LPC, ligand presenting cell; CD, cluster of differentiation; DC, dendritic cells; ICD, International Statistical Classification of Diseases and Related Health Problems Ninth Revision; I/R, ischemia/reperfusion; IL, interleukin; mAb, monoclonal antibody; MFI, mean fluorescence intensity
Amelioration of EAMC through activation of iNKT cells by administration of \(\alpha\)-GC

Introduction

Myocarditis has been defined as "the presence of cellular inflammatory infiltrate in direct association with necrosis or degeneration of myocytes not typical of ischemic necrosis" accompanied with cardiac dysfunction.\(^1\) The causes of myocarditis include infections by viruses, bacteria, fungi, and parasites, cardiotoxic drug-induced, autoimmunity-related, and others that are recapitulated as idiopathic.\(^2\) The prevalence of cases worldwide is estimated to be approximately 22/100,000/year according to the ICD-9 codes.\(^3\) Myocarditis is one of the causes of sudden death (12%) among juvenile and adolescent population with a prevalence of 1/200,000/year.\(^4\) However, the severity of the disease is variable with minimal symptoms that make it difficult to diagnose lethal cases that are accompanied with severe myocardial damage that result in fetal arrhythmia and cardiogenic shock, which makes the prevalence underestimated.\(^5\)

The myocardial damage and the resultant loss of cardiomyocytes due to any etiology are filled primarily with fibroblasts and compensated by hypertrophy of surviving cardiomyocytes. The process of cardiac remodeling, for repairing damaged cardiac muscles and compensation of cardiac function, often results in heart failure causing fatalities.\(^6,7\) Moreover, because the causes and development are variable, it is difficult to effectively control the inflammation and remodeling processes.\(^2,8\) Therefore, the prevention and effective therapeutics for myocarditis and cardiac remodeling must be developed.

NKT cells are a subset of T cells that are restricted by the CD1d molecule.\(^9\) The majority of NKT cells express the invariant TCR \(\alpha\) chain (TRAV11AJ18) and are classified as type I NKT or iNKT cells. iNKT cells recognize glycolipid Ag such as \(\alpha\)-GC and exhibit various functions as exemplified as a Swiss-army knife.\(^10\) iNKT cells are able to function not only as effector cells that exhibit cytotoxic activity through perforin and Fas ligands but also as regulatory cells through production of IL-10 and tumor growth factor-\(\beta\) in immune responses.\(^10\) Accordingly, iNKT cells have been shown to modulate disease progression in various disease models to date.\(^11,10\)

NKT cells have been reported to be recruited to infarcted lesions following AMI model in mice and to ameliorate the cardiac remodeling upon activation with \(\alpha\)-GC.\(^13\) Furthermore, the beneficial effect of iNKT cells has been reported in cardiac remodeling following ischemia/reperfusion injury models in mice.\(^15\) Regarding EAMC models, it has been reported with BALB/c mice immunized with purified protein of porcine cardiac myosin that \(\alpha\)-GC administration ameliorated the inflammation.\(^15\) Although a single dose of \(\alpha\)-GC as an immunization ameliorated the myocarditis with increased NKT cells and Treg cells, the involvement of NKT cells in this particular model and the relation with Treg cells remained elusive. Thus, we examined the effect of NKT-cell activation to mitigate EAMC in BALB/c mice and investigated a possible mechanism for amelioration.

Materials and Methods

Mice

Male and female, 6-week-old BALB/c mice were purchased from CLEA Japan, (Tokyo) and TRAJ18 gene (prepared by CRISPR/Cas9 gene editing; Traj18\(^{14}\)) mice were obtained from the Institute of Medical Sciences, The University of Tokyo, and were maintained at the Animal Facility in Kitasato University School of Medicine. The mice were maintained on food and water \textit{ad libitum} with a 12-hour light/12-hour dark cycle, treated humanely, and housed in specific pathogen-free conditions at the Animal Facility in Kitasato University School of Medicine. All the experimental procedures on the mice conformed to the Animal Experimentation and Ethics Committee of the Kitasato University School of Medicine (2016-109, 2017-143, 2018-118, -119, 2019-024, -025).

Reagents

The authentic peptide residue 614-629 of mouse MyHC-\(\alpha\)614-629 (Ac-SLKLMATLFSTYASAD)\(^17\) and the modified form of MyHC-\(\alpha\)614-629 with arginine residues (R) at both amino (N)-terminal and carboxy (C)-terminal ends (MyHC-\(\alpha\)614-629R: Ac-RLKLMATLFSTYASAD) that do not appear in the original sequence of MyHC-\(\alpha\)\(^18\) were synthesized and purchased from Sigma-Genosys Japan (Ishikari) and Hokkaido System Science (Sapporo). Purified PTX was purchased from Sigma-Aldrich (St. Louis, MO, USA). CFA was purchased from Calbiochem-Sigma Aldrich (global) and Mycobacterium tuberculosis strain H37Ra from Difco (Detroit, MI, USA). \(\alpha\)-GC was purchased from Funakoshi (Tokyo) or provided by Wako Pure Chemical Industries (Osaka).

Induction of EAMC in mice and administration of NKT-ligands with inoculum

To induce EAMC, MyHC-\(\alpha\)614-629 or MyHC-\(\alpha\)614-629R (100 \(\mu\)g) was emulsified in CFA (1:1 v/v) containing 5 mg/ml Mycobacterium tuberculosis H37Ra (Difco) and a total of 200 \(\mu\)l of the emulsion was subcutaneously injected in the upper and lower parts of the back.\(^17,18\) When mice were treated with the NKT-cell ligand, \(\alpha\)-GC
Flow cytometric analyses

The cells were incubated with 2.4G2 mAb (anti-FcγRIII/II) to block non-specific binding of primary mAb and then stained with combinations of various specific mAbs. Stained cells were acquired with FACS Verse or FACS Aria flow cytometers (BD Bioscience, San Jose, CA, USA) and analyzed with FlowJo software (Tree Star, Ashland, OR, USA). Any and all 7-aminoactinomycin D (7-AAD; BD Bioscience) positive cells were electronically gated as dead cells from the analysis. Anti-mouse mAbs used in this study were as follows. APC-conjugated mAb: anti-CD11b (M1/70, BioLegend, San Diego, CA, USA), anti-CD11c (N418, BioLegend), anti-CD103 (αE integrin; 2E7, BioLegend), anti-CD115 (CSF1R; AFS98, BioLegend), anti-Ly6C (HK1.4, BioLegend), anti-CD169 (Siglec-1; 3D6.112, BioLegend), and anti-Feeder Cells (MEFSK4, Miltenyi Biotec). APC/Cy7-conjugated mAb: antiCD45 (30-F11, BioLegend) and anti-TCRβ (H57-597, BioLegend). Brilliant Violet-conjugated mAb: anti-F4/80 (BM8, BioLegend Japan, Tokyo). FITC-conjugated mAb: anti-CD1d (1B1, BioLegend), PE-anti-CD1d (1B1, BioLegend), anti-MERTK (2B10C42), anti-MHC-II (I-Ad) (NIMR-4, eBioscience), anti-ICOSL (CD275) (B7H2, BioLegend), and anti-CCR2 (CD192) (SA203G11, BioLegend). PE/Cy7-conjugated mAb: anti-CD11b (M1-70, BioLegend). APC-labeled α-GC-loaded tetramer and unloaded CD1d-tetramer for analyses of iNKT cells were provided by the National Institutes of Health Tetramer Core Facility at Emory University (Atlanta, GA, USA).19,21

Proliferative responses and cytokine production upon antigen stimulation

dLN cells were obtained from mice 10 days after immunization and were used with the T-cell Recovery Kit (Cedarlane, Ontario, Canada) according to the manufacturer’s protocol. The dLN cells were incubated with reagents supplied in the kit and applied to recovery columns to obtained T-enriched cells as flow through fractions. T cells (2 x 10⁶) from each group were cultured in complete medium (RPMI [Roswell Park Memorial Institute]-1640) (Sigma), supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin, 100 μg/
ml streptomycin, and 50 μM β -mercaptoethanol with irradiated splenocytes (1 × 10^6) as APC in the presence of MyHC-α peptides (0.01–1 μg/ml) for 3 days. The spleen cells for APC were enriched for dendritic cell fractionation by preparing the cells in the interface of density centrifugation with 55% Percoll. The concentration of cytokines was quantified in the supernatant of the above culture by a CBA (cytometric bead array) kit (BD Bioscience) according to the manufacturer's protocol with a flow cytometer. For proliferation assay, cells of the above setup in culture plates were then pulse-labeled with ^3H-thymidine (^3H-TdR; 0.5 μCi/well) for the following 16 hours. The ^3H-TdR incorporation of each well was quantified with a liquid scintillation counter.

**PCR**

Total RNA was extracted from either prepared suspension of single cells from each tissue or a part of excised piece of cardiac tissue using TRIzol reagent (Life Technologies) and with shaker homogenizer for a tissue piece (heart). cDNA was synthesized with 1 μg of total RNA by PrimeScript RT Master Mix (Takara Bio, Shiga). Synthesized cDNA was diluted appropriately with water and used as a template for subsequent quantitative PCR. Quantitative PCR was performed with SYBR Premix Ex Taq II (Takara Bio) and CFX96/384 (Bio-Rad, Hercules, CA, USA) according to the manufacturer's protocols. Target gene expression was normalized by β-actin and calculated by the 2-ΔΔCT method. Primers were as follows:

- **actb**
  - forward: 5'-GGCTGTATCCCCCTCCATCG-3'
  - reverse: 5'-CCAGTTGGTAAACAAATGCTATG-3'

- **tnfa**
  - forward: 5'-GGCACCACGCTTCTGTCTAC-3'
  - reverse: 5'-GGGTTCTGGGCCATAGACTT-3'

- **acta2**
  - forward: 5'-AAGAGGAAGACAGACAGCC-3'
  - reverse: 5'-AGCGTCAGGATCCCTCTCTT-3'

- **col1a1**
  - forward: 5'-CCAGCCGCAAAGAGTCTACA-3'
  - reverse: 5'-CATACCTCGGGTTTCCACGT-3'

- **col3a1**
  - forward: 5'-GCGAGCGGCTGAGTTTTATG-3'
  - reverse: 5'-GGGTCTGGGCCATAGAACTGAT-3'

- **il10**
  - forward: 5'-GGCTCTTAAGCTGCTGCTGCATGAG-3'
  - reverse: 5'-GCCAGCTCTAGGAGCATGTG-3'

- **ccl2**
  - forward: 5'-CCCAATGAGTAGCTGGAGA-3'
  - reverse: 5'-GGTACTGCTGAAGGGCAAG-3'

- **cil1d**
  - forward: 5'-ACTCCAGGAGCCCACTCAGCTTC-3'
  - reverse: 5'-GGTGACATTTCACAGCCCG-3'

- **cil16**
  - forward: 5'-CCTTGTCTTCTGTCATGGT-3'
  - reverse: 5'-CTCAAGTACATTCAGCAGCCG-3'

- **il17**
  - forward: 5'-TGAAAGCGCCAGCAGATCA-3'
  - reverse: 5'-GGAGTCTCCTGGCCTCAGTGT-3'

- **il4**
  - forward: 5'-GGTCTCATTCCAGTCCTCTT-3'

**Figure 1.** The F4/80^+^CD11b^+^ fraction is the main CD1d-expressor in the heart.

Cardiac mononuclear cells were prepared by digestion of the heart tissue with collagenase D and DNase I and analyzed with flow cytometer as described in the Materials and Methods. A. Flow cytometric profiles. a. Forward scatter (FSC) vs. Side scatter (SSC) plot. b. CD45 vs. SSC plot. c. CD11b vs. F4/80 plot. e. MEFSK4 vs. CD31 plot. f. CD11b vs. Ly6C plot. j. F4/80 vs. SSC plot. k. CD11b vs. CD11c plot. Panels (d, g, i, l) of CD1d histogram of macrophage (d. Mφ; CD11b^+^F4/80^+^), monocyte (g. Mo; CD11b^+^Ly6C^+^), endothelial cell (h. MEFSK4^+^CD31^+^), cardiac fibroblast (i. MEFSK4^+^CD31^+^) and dendritic cell (l. DC; CD11b^+^CD11c^+^). B. Mean fluorescence intensity (MFI) of CD1d staining of each population, Mφ (black column), Mo (gray column), and DC (white column). Representative results of at least five independent experiments (n = 3–4 mice/time) were shown. Graph data are shown as mean ± SD.
reverse 5'-CACAGCAACGAAGAACACCAC-3'
ifng forward 5'-TCAAGTGGCATAGATGTGGAAGAA-3'
reverse 5'-TGGCTCTGAGATTTTCATG-3'

Statistical analyses
Data are shown as mean ± standard deviation (SD). Statistical analysis between two groups was performed by Student’s t-test and among three groups was performed using ANOVA followed by Tukey-Kramer tests. Values with P < 0.05 were considered statistically significant. The significance (P < 0.05) of the difference between two mean clinical scores was determined by the non-parametric Mann-Whitney U-test for comparison of two independent populations.

Results
CD1d expressing cells in the heart
First to examine CD1d+ cells that are capable to present α-GC to iNKT cells in the heart, CD1d expression was analyzed on cardiac mononuclear cells obtained from BALB/c mice. Figure 1 shows a scheme of gating strategy to analyze each population for the expression of CD1d according to previous report.18,20 The CD45+ cells were further separated with the expression of CD11b and F4/80 to detect Mφ (Figure 1Ab,c,d). In a similar way, the CD11b+F4/80lo fraction were further developed CD11bLy6Chi to detect Mo (Figure 1Ab,c,f,g). The F4/80+ fraction of CD45+ cells was separated with the expression of CD11b and CD11c to detect DC (Figure 1Ab,j,k,l). Although these 3 populations were positive for CD1d expression (Figure 1Ad,g,l), Mφ exhibited the highest MFI in CD45+ cells in the heart (Figure 1B). Meanwhile, the CD45+ fraction of cells was separated with MEFSK4 and CD31 to detect cardiac endothelial cells (CD31+MEFSK4+; Figure 1Ae,h) and cardiac fibroblasts (CD31 MEFSK4+; Figure 1 Ae,i) was both negative for CD1d.

Figure 2. Expression of surface markers on F4/80+CD11b+ cardiac Mφ in untreated BALB/c mice
Cardiac mononuclear cells were stained with F4/80/CD11b indicated mAb and the results were expressed as a histogram. Numbers in the histogram panels represent MFI of isotype control (gray) or indicated mAb staining (black).
Amelioration of EAMC through activation of iNKT cells by administration of α-GC

Figure 3. Cellular responses of antigen presenting cells and NKT cells in the heart tissue before, at 1 day, and 1 week after intraperitoneal administration of α-GC

A. Cell counts (a,d), CD1d expression (b,e), and MFI of CD1d staining (c,f) of Mφ (a,b,c) or Mo (d,e,f), respectively at each time point.  
B. Gene expression by iNKT cells with quantitative PCR analyses for indicated genes before and after administration of α-GC at each time point.  (n = 3 mice for each group.  Representative of two independent experiments with similar results were shown.  Graph data are shown as mean ± SD. *P < 0.05, **P < 0.01

Figure 4. Cellular dynamics and gene expressions in the heart tissue at each time point

A. Upper panels: cell count/g tissue of the indicated subset of cells in the hearts at days 0, 14, 21, 28, and 60 after immunization with α-GC. Lower panels: Percentages of cells in the cardiac mononuclear cells obtained from the heart tissue at the same time as those in the upper panels. Inset is demonstrated with different numerical values in the y-axis to better depict fluctuations.  
B. Expressions of genes indicated in each panel at each time point as above (A). Three mice for each time point were analyzed. Representative of two independent experiments with similar results are shown. Graph data are shown as mean ± SD.
A. Histopathology of the heart tissue obtained from mice administered vehicle or α-GC and stained with H&E or Masson’s trichrome solution. Magnification ×5, Inset ×20. B. Fibrotic lesion areas of mice administered vehicle or α-GC. C. Expression of genes indicated in each panel of the heart tissue in comparison with vehicle- or α-GC-treated mice (n = 5 for control group, n = 4 for α-GC administration group). D. Proliferative response of T cells obtained from dLN (draining lymph node) of EAMC-induced mice (n = 3 for each group) with vehicle (control) or α-GC administration (α-GC) after 21 days of primary immunization. T-enriched cells were cultured at each concentration of MyHC-α peptide in the presence of antigen-presenting cells (APCs) as described in Materials and Methods. 3H-TdR incorporation by T cells at each concentration of MyHC-α peptide was quantified with scintillation counter. E. Cytokine concentration in culture supernatant (pg/ml). The concentration of IFN-γ, TNF-α, and IL-17 was quantitated in triplicate culture. Representative data of three independent experiments with similar results are shown. Graph data are shown as mean ± SD. *P < 0.05

Figure 5. Effect of α-GC administration on development of EAMC in BALB/c mice
The expression of other surface markers of F4/80+CD11b+ cardiac Mφ
To explore other surface markers on cardiac Mφ, F4/80+CD11b+ cells were further stained with anti-mouse mAb and analyzed with flow cytometer (Figure 2). Cardiac Mφ was clearly positive for MerTK, MHC class II (mixed population of low and high), CD86, CD206 (macrophage mannose receptor; CLEC13D), CX3CR1; weakly positive for CD80; minimally positive to negative for ICOSL (CD275), CCR2 (CD192), CD11c, CD103 (αE integrin), and CD115 (CSF1R); and presumably a fraction of cells are positive for Ly6C in steady state. Regarding other markers not included in Figure 2, CD169 (Sialoadhesin, Siglec-1) was negative and CD210 (IL-10R-α) was weakly positive (data not shown).

Cellular responses after α-GC administration
To examine cellular responses and dynamics in the heart following administration of α-GC, the main CD1d+ cells in the heart, cardiac macrophages (Mφ) and monocytes (Mo) were analyzed. The Mφ exhibited an increase in cell counts, and the MFI level of CD1d expression one day (day 1) after α-GC administration and the cell counts stayed at a similar level at 1 week as that of day 1; whereas the MFI of CD1d returned to the control level at 1 week (Figure 3Aa,b,c). On the other hand, Mo exhibited the marked increase of cell counts at day 1 but appeared to be in a decreasing trend. The up-regulation in MFI of CD1d was observed at day 1 after α-GC administration but appeared minimal compared to that of Mφ (Figure 3Ad,e,f). When the expression of indicated genes was analyzed, those of Ifi4, Ifng, and Ccl2 that are presumably produced by NKT cells appeared to be up-regulated at day 1 and returned to control level at 1 week (Figure 3B). Meanwhile, the expression of Cxcl16 appeared to gradually increase, but the other genes did not exhibit distinct patterns.

Analyses of cellular dynamics and gene expression in the hearts of mice-induced EAMC: a kinetic study
Dynamics of CMNC obtained from cardiac digests and gene expression of the heart were analyzed with flow cytometer or with real time PCR at each time point (days 0, 14, 21, 28, 60) in mice that were induced EAMC. The number of cardiac Mφ gradually increased after induction to day 60, whereas those of Mo showed a small peak at day 14 and then appeared to decrease, which similarly observed in both Ly6Clo and Ly6C hi population as shown in inset. Notably, the number of cells appeared about ten times more for Ly6Clo compared to that of Ly6Chi population (Figure 4A upper panel/inset). As for DC,

the kinetics was similar to that of Mo as shown in inset figure, though the numbers were smaller than Mφ and Mo fractions. The ratio to the total mononuclear cells obtained from the heart appeared to reflect the dynamics (Figure 4A lower panel). There seemed a decrease in the ratio of Mφ at day 14 presumably due to an increase of Ly6C hi Mo. Of note, iNKT cells appeared to be detected at day 21, peaked at day 28 and decreased to the level of day 21 at day 60. This tendency was reproducible in other setup for this kinetic assay. The increase of iNKT cells around day 28, the expression of Il10 and Tnfa appeared to be similarly up-regulated at the timing. Moreover the expressions of Ccl2 and Cxcl16 appeared to be enhanced in earlier phase (days 14 and 21, respectively), which might be related with the cellular dynamics demonstrated above (Figure 4B).

Administration of α-GC at the immunization ameliorated the cardiac inflammation and fibrosis.
We assumed from above experiments that an administration of α-GC was able to induce cellular responses in the heart presumably via activation of iNKT cells and the involvement of iNKT cells during induction and development of EAMC even in the absence of administration of α-GC. Thus, we attempted to administer α-GC to modulate immune responses against MyHC-α that induce EAMC at the time of immunization according to our previous experiments with EAU.19 To examine effects of the administration, the acute inflammation induced by immunization with MyHC-α peptide was evaluated on day 21. Control mice showed significant infiltration of inflammatory cells in H&E staining and fibrosis detected as blue-green area in Masson's trichrome staining (Figure 5A upper panels). On the other hand, α-GC administered mice exhibited the lesser infiltrated cells and smaller areas of fibrosis (Figure 5A lower panels). The fibrotic area was smaller in α-GC administered mice compared with that of control Figure 5B). When the gene expression was analyzed with the heart at day 21, pro-inflammatory cytokines, Tnfa and Il6 appeared down-regulated whereas Il10 was in increasing trend (Figure 5C).

To examine the immune responses of T cells obtained from the dLN cells, proliferative response estimated by 3H-TdR incorporation and cytokine production in the culture supernatant with flow cytometer were compared at d 21 after immunization between control and α-GC-treated groups of mice as shown in Figure 5D,E. There was no difference in proliferative responses between two groups (Figure 5D). Although there were differences in the expression of several cytokines in the heart at day 21,
A. Histopathology of the heart obtained from EAMC-induced WT (BALB/c) and TRAJ18⁻/⁻ (BALB/c background) mice and stained with Masson's trichrome and H&E solution. Magnification ×4; ×20. In H&E stain, circled area was set to see infiltration of inflammatory cells in the heart tissue. B. Histograms of the fibrotic lesion areas. C. Quantification of myocardial enzyme and molecules released by inflammatory response. Creatine kinase and cTnI levels were quantified as described in the Materials and Methods. D. Proliferative responses after 10 days of the primary immunization in WT or TRAJ18⁻/⁻ mice. The incorporation of ³H-TdR was quantified by scintillation counter. T-enriched cells from dLN of EAMC mice (n = 3 each group) cultured were at each concentration of MyH5 peptide in the presence of APCs as described in Materials and Methods. Prior to the pulse labeling with ³H-TdR, supernatant of each well was collected for quantification of cytokines as shown in E. E. Cytokine concentration in culture supernatant (pg/ml) was quantified with CBA (cytometric bead array) as described in Materials and Methods. The concentration of indicated cytokines was quantitated in triplicate culture. Representative of two independent experiments with similar results are shown. Graph data are shown as mean ± SD. *P < 0.05

Figure 6. EAMC induced in the absence of iNKT cells with TRAJ18⁻/⁻ mice.
Amelioration of EAMC through activation of iNKT cells by administration of α-GC

there were no differences in the production of IL-17, TNF-α and IFN-γ at this time point presumably because the main site of T cell activation was in the cardiac tissue (Figure 5E).

**Acute inflammatory responses appeared aggravated in TRAJ18−/− mice where iNKT cells were deficient.** If iNKT cells played the beneficial role in mitigating cardiac inflammation, EAMC induction in iNKT-deficient mice may cause deteriorating effect for the cardiac inflammation. Indeed, EAMC induced in TRAJ18+ mice exhibited enhanced infiltration of inflammatory cells and aggravated fibrosis compared to those of WT BALB/c mice (Figure 6A). The fibrotic lesion areas were significantly larger than those of WT mice (Figure 6B). Serum level of creatine kinase and troponin I that indicate the tissue damages of the heart appeared higher in TRAJ18−/− mice than those of BALB/c mice (Figure 6C). Meanwhile, when the antigen-specific T cell response was analyzed at day 10 after the primary immunization however, there was no difference in 3H-TdR incorporation between WT and TRAJ18−/− mice at day 10 after immunization (Figure 6D). The cytokine production in the supernatant by the T cells obtained from dLN cells of EAMC-induced WT or TRAJ18−/− cultured in the presence of MyHC-α peptide with APC was examined, the reduced production of IL-2, whereas slightly enhanced production of IFN-γ but not that of TNF-α were noted in TRAJ18−/− mice (Figure 6E).

**Discussion**

In the present study, the early activation of NKT cells ameliorated EAMC in BALB/c mice when the mice were administered the α-GC with the immunization inoculum. The amelioration appeared to be related the up-regulation of IL-10 and the down-regulation of the expression of pro-inflammatory cytokines, ifna and il6. The fibrotic lesion area was reduced in the group that received administration of α-GC at the time of immunization. The finding that iNKT cell may have beneficial effect was reinforced by the finding that EAMC induced in iNKT-cell deficient strain TRAJ18−/− mice in the BALB/c background was aggravated with larger fibrotic lesion areas than those of WT mice.

The administration of α-GC in aqueous solution induced rapid activation of iNKT cells in the heart at day1 that led to the expressions of Il4, Ifng, and Ccl2 (Figure 3). The complex formed with the administered α-GC and CD1d was detected on MΦ but not on Mo with L363 mAb23 after day 1 of the injection (data not shown), suggesting that the complex on MΦ stimulated iNKT cells to express Il4 and Ifng, and Ccl2 to recruit Mo (Figure 3). The response was transient because the NKT cell ligand might have been washed away and disappeared by day 7. When EAMC was induced in the BLAB/c mice without α-GC administration, iNKT cells appeared around days 21−28 along with the development of an inflammatory disease (Figure 4). Because we did not examine CD1d molecules with L363 mAb on Mo (Figure 3). The response was transient because the development of EAMC could be aggravated. Indeed, the fibrotic lesion areas were enhanced in TRAJ18−/− mice, and myocardial injuries assumed by released creatine kinase and troponin I were higher in TRAJ18−/− mice (Figure 6). Therefore, the hypothesis that iNKT cells may have beneficial effects on the development of EAMC was also confirmed.

Liu et al.14 demonstrated that α-GC administration ameliorated the EAMC in their previous report. EAMC was induced in BALB/c mice by immunizing with whole protein of porcine cardiac myosin. The mice were administered α-GC intraperitoneally at the time of immunization and injected on alternate days for 6 weeks. The myocardial inflammation improved in the α-GC treated group compared to the control group. They assumed that the NK1.1+ iNKT cells and Treg cells were involved with the amelioration with the up-regulation of MMP2 and MMP9 in the heart presumably for the clearance/repair of the inflammatory lesion. Because NK1.1 is not expressed in BALB/c strains of mice, the study remained to be pursued. The present study has clearly demonstrated the involvement of iNKT cells through detection them by not only using real time PCR and flow cytometric analyses but also by using iNKT-deficient mice as a model. Liu et al.’s report implied that Treg cells were involved in the amelioration of EAMC. We have not examined that involvement and will, therefore, pursue in further investigations. In
TRAJ18/− mice, the low induction of IL-2 by Ag-specific T-cell response may be related to a dysfunction of Treg cells leading to the enhanced pathology, a topic which also warrants further examination.

In previous studies of AMI and I/R model in mice, α-GC administration also exhibited beneficial effect on cardiac remodeling and function following induction of the diseases with elevated expression of IL-10, an anti-inflammatory cytokine.12,13 Anti-IL-10 antibody administration abolished the effect of α-GC administration, suggesting that the effect was mediated through production of IL-10 by iNKT cells through the suppression of inflammatory responses. In AMI model, the improvement of cardiac remodeling by IL-10 is mediated by the Mφ polarization towards M2 and the activation of fibroblast.24 Besides IL-10, IL-4 has been reported as an amelioration-inducing cytokines in AMI model,25,26 which seems also reasonable because IL-4 could function as an inducer of type 2 immunity that allows M2-Mφ accumulation. However, The reports that IL-10 from Mφ may promote diastolic dysfunction27 or that IL-4 of eosinophil origin may progress dilated cardiomyopathy28 also tell us that the specific functions of cytokine does not always bring beneficial outcomes.

Meanwhile, LPCs in the heart are not fully understood that present α-GC to iNKT cells for the induction of IL-10 in models in which beneficial effect has been obtained to date.13,14 In the present study, we attempted to search candidate for LPCs in the heart by digesting a part of the hearts and found that cardiac Mφ expressed the highest level of CD1d among CMNC and could serve as LPCs in the heart and were actually shown by L363 mAb that detects α-GC/CD1d complex when mice were exogenously administered the ligand.23,29 We assumed the possibility from our results that Mφ is the major and CD1d+- population among cardiac mononuclear cells. However, to test whether the Mφ is a critical LPC on α-GC administration that exhibits beneficial effects, conditional knockout mice should be employed that carried disrupted alleles of cd1dl gene specifically in Mφ30,31 in mice of BALB/c background, which remains to be performed.

At least a part of Mφ obtained from digested cardiac tissue appeared to retain characteristics of primitive Mφ expressing MHC IIα and CXCR1. Cardiac Mφ seeded during embryogenesis by yolk sac progenitors and fetal liver seems to have resident-type characteristics but not as fixed as microglia and slowly replaced by blood monocytes,32-34 and continue to play anti-inflammatory role following pathological state such as ischemic injuries and infections in cardiac micro-environment by bias towards M2-Mφ or M2-Mφ-like, reparative Mφ.35 Notably, when M1- vs. M2-bias was examined in α-GC-treated vs. vehicle control and in wild type BALB/c mice vs. TRAJ18/− mice, apparent bias towards M2-Mφ or reduced M1 proportion were not always observed or did not appear as anticipated manner, although in a steady state, cardiac tissue seems to be protected by a cardiac M2-Mφ environment.

In summary, iNKT cells exhibit ameliorating function when activated at the time of immunization and the presence of iNKT cell in WT mice appears beneficial in comparison with mice of NKT-deficient strain. The latter finding that TRAJ18/− mice had aggravated inflammation in the heart implicates that an endogenous ligand in the context of CD1d on Mφ as LPCs stimulate iNKT cells to induce favorable response to reduce inflammatory destruction of myocardium. The cardiac Mφ appeared CD206+ population in steady state and are able to support anti-inflammatory environment as M2-Mφ. In the present study, α-GC was administered at the immunization period as preventive regimen. Administration of α-GC after immunization preferably after the onset may open further application for treatment of EAMC as a model of human diseases. Employment of specified iNKT cell ligands such as Th1- or Th2-based activity may also be explored for better induction of ameliorating effects via iNKT cells. Therefore, further investigation is warranted because iNKT cell-cardiac Mφ interaction appears to be a promising target to help prevent or treat myocarditis, and because we have not, so far, been able to trace the long-term outcome more than 60 days after an administration of α-GC on cardiac remodeling.

Acknowledgements

We thank the NIH Tetrramer Core Facility for generously providing the α-GC/CD1d tetramer. This study was supported by the Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research [C] [no. 17K0879 to K.I. and M.S.], [C] [no. 19K09011 to M.S.]); by an A-MED grant (no. 16ek019076s0202 to K.I.); by MEXT (Grant-in Aid for the Strategic Research Foundation at Private University [no. S1411002]; Grant-in-Aid for Research Branding Project: Agromedicine at Kitasato University and Research Grant for Young Researchers (to M.S.) by Kitasato University.

Conflicts of Interest: None
References


